Literature DB >> 27444273

Note of the methodological flaws in the paper entitled "GSTT1 and GSTM1 polymorphisms predict treatment outcome for breast cancer: a systematic review and meta-analysis".

Mali Qiu1, Xu Wu1, Xiaobing Qu2.   

Abstract

With great interest, we read the paper "GSTT1 and GSTM1 polymorphisms predict treatment outcome for breast cancer: a systematic review and meta-analysis" (by Hu XY et al.), which has reached important conclusions that GSTM1 null and GSTT1/GSTM1 double null polymorphisms might be significantly associated with an increased tumor response in breast cancer. The result is encouraging. Nevertheless, several methodological flaws in this meta-analysis are worth noticing.

Entities:  

Keywords:  Breast; GSTM1; GSTT1; Meta-analysis; Polymorphisms

Mesh:

Substances:

Year:  2016        PMID: 27444273     DOI: 10.1007/s13277-016-5154-3

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  4 in total

1.  Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses.

Authors:  Andreas Stang
Journal:  Eur J Epidemiol       Date:  2010-07-22       Impact factor: 8.082

Review 2.  GSTT1 and GSTM1 polymorphisms predict treatment outcome for breast cancer: a systematic review and meta-analysis.

Authors:  Xue-Ying Hu; Xiang-Yang Huang; Jie Ma; Yang Zuo; Ning-Bin Luo; Shao-Lv Lai; Dan-Ke Su
Journal:  Tumour Biol       Date:  2015-11-14

Review 3.  Evaluating non-randomised intervention studies.

Authors:  J J Deeks; J Dinnes; R D'Amico; A J Sowden; C Sakarovitch; F Song; M Petticrew; D G Altman
Journal:  Health Technol Assess       Date:  2003       Impact factor: 4.014

4.  The role of anti-VEGF agents in the treatment of advanced gastric cancer: a meta-analysis of randomized controlled trials.

Authors:  Wei-Xiang Qi; Zan Shen; Li-Na Tang; Yang Yao
Journal:  Tumour Biol       Date:  2014-05-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.